BioSpace News Archive

ScandiDos AB and Varian Medical Systems have completed verification and validation of the Delta4 Discover system for use on TrueBeam and Clinac Ix radiotherapy systems [15-November-2017] UPPSALA, Sweden, Nov. 15, 2017 /PRNewswire/ -- ScandiDos AB (NASDAQ OMX First North: SDOS), a global leader in Quality Assurance (QA) and dosimetry for modern radiation thera

The joint venture follows a strategic collaboration between Helomics and Skyline announced on November 1, 2017 and represents a deeper partnership between the two companies that is expected to provide Skyline with opportunities to generate revenues from additional markets.

Cash, cash equivalents and financial assets of the Company amounted to €195.7 million at September 30, 2017, including current and non-current financial assets (€239.6 million at September 30, 2016).

Mr. Kanter has more than 30 years of experience in the financial services industry.

Data from MyoKardia’s in vivo study demonstrated that treatment with mavacamten improved myocardial compliance while preserving systemic pressures.

Enrollment of the first cohort (Cohort A) is now complete. Participants in Cohort A received two CYP-001 infusions each at the lower dose level (1 million cells/kg, up to a maximum of 100 million cells per infusion).

The company expects to receive further communication from the FDA within 30 days.

FDA Prescription Drug User Fee Act goal date set for August 30, 2018.

For the nine months ended September 30, 2017, the Company reported a net loss of approximately $11.9 million.

The study suggests that patients with these cancers could benefit from targeted therapy based on the detection of biomarkers found with a comprehensive liquid biopsy, but that were absent from their primary tumor.